[1]张灿 李宝新 郭淑芹 常文龙 王翯 姚琪 张云良.2型糖尿病合并肥胖患者血清Irisin 和SFRP5水平变化的研究[J].国际内分泌代谢杂志,2018,38(01):1-5.[doi:10.3760/cma.j.issn.1673-4157.2018.01.001]
 Zhang Can*,Li Baoxin,Guo Shuqin,et al.The changes of serum Irisin and SFRP5 levels in obese patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(01):1-5.[doi:10.3760/cma.j.issn.1673-4157.2018.01.001]
点击复制

2型糖尿病合并肥胖患者血清Irisin 和SFRP5水平变化的研究()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年01期
页码:
1-5
栏目:
论著
出版日期:
2018-01-20

文章信息/Info

Title:
The changes of serum Irisin and SFRP5 levels in obese patients with type 2 diabetes mellitus
作者:
张灿 李宝新 郭淑芹 常文龙 王翯 姚琪 张云良
067000 承德医学院(张灿、姚琪); 071000 保定市第一中心医院内分泌科(李宝新、郭淑芹、常文龙、王翯、张云良)
Author(s):
Zhang Can*Li BaoxinGuo ShuqinChang WenlongWang HeYao QiZhang Yunliang.*
Chengde Medical College,Chengde 067000,China
关键词:
2型糖尿病 肥胖症 Irisin 分泌型卷曲相关蛋白5
Keywords:
Type 2 diabetes mellitus Obesity Irisin Secreted frizzled related protein 5
DOI:
10.3760/cma.j.issn.1673-4157.2018.01.001
摘要:
目的 探讨2型糖尿病合并肥胖患者血清鸢尾素(Irisin)和分泌型卷曲相关蛋白5(SFRP5)水平的变化。方法 选取2015年10月至2016年12月在保定市第一中心医院内分泌住院的195例2型糖尿病患者,根据体重指数分为糖尿病正常体重组(n=71)、糖尿病超重组(n=70)、糖尿病肥胖组(n=54),同期体检体重指数正常的健康受试者为对照组(n=50),分别比较4组一般资料、血清Irisin及SFRP5水平的差异,采用Spearman相关性分析法分析血清Irisin和SFRP5与体重指数、腰臀比、血脂、血糖的相关性,多元逐步回归分析血清Irisin和SFRP5与相关代谢指标的关系。结果 与糖尿病正常体重组和糖尿病超重组相比,糖尿病肥胖组空腹胰岛素(FINS)、稳态模型评估-胰岛素抵抗指数(HOMA-IR)明显增加(χ2=17.8519.63,P均<0.05),血清Irisin、SFRP5水平明显下降(F=51.70、15.13,P均<0.05)。 Spearman相关性分析显示,血清Irisin水平与体重指数、腰臀比、总胆固醇、甘油三酯、FINS、HOMA-IR呈负相关(r=-0.77~-0.23,P均<0.05),与高密度脂蛋白-胆固醇(HDL-C)、SFRP5呈正相关(r=0.200.22,P均<0.01); 血清SFRP5水平与体重指数、腰臀比、糖尿病病程、甘油三酯、低密度脂蛋白-胆固醇、HbA1c、FINS、HOMA-IR呈负相关(r=-0.38~-0.13,P均<0.05),与HDL-C、Irisin呈正相关(r=0.170.22,P均<0.05)。多元逐步回归分析显示体重指数、腰臀比、FINS与血清Irisin呈显著负相关(β=-0.04、-2.75、-2.27,P均<0.05),体重指数与血清SFRP5呈显著负相关(β=-1.14,P<0.05)。结论 2型糖尿病合并肥胖时血清Irisin和SFRP5水平均显著降低,二者可能在糖尿病合并肥胖的发病中发挥一定作用。
Abstract:
Objective To study the changes of serum Irisin and secreted frizzled-related protein 5(SFRP5)levels in obese patients with type 2 diabetes mellitus.Methods A total of 195 patients with type 2 diabetes hospitalized in the Department of Endocrinology of the First Central Hospital of Baoding City from October 2015 to December 2016 were divided into diabetic normal weight group(n=71), diabetic overweight group(n=70)and diabetic obesity group(n=54)according to body mass index(BMI). Another 50 healthy subjects with normal BMI in the same period were included as control group(n=50). The general information and serum Irisin and SFRP5 levels were compared among 4 groups. Spearman correlation analysis was used to analyze the correlation between serum Irisin, SFRP5 and BMI, waist to hip ratio(WHR), blood lipid and blood glucose. Multiple stepwise regression analysis was used to analyze the relationship between serum Irisin, SFRP5 and related metabolic indexes.Results Compared with diabetic normal weight group and diabetic overweight group, fasting insulin(FINS)and homeostasis model assessment-insulin resistance index(HOMA-IR)were increased(χ2=17.85,19.63,all P<0.05),whereas the levels of serum Irisin and SFRP5 were declined(F=51.70,15.13,all P<0.05)in diabetic obesity group. Spearman correlation analysis showed that serum Irisin was negatively correlated with BMI, WHR, total cholesterol(TC), triglyceride(TG),FINS,and HOMA-IR(r=-0.77--0.23,all P<0.05),but positively correlated with high density lipoprotein-cholesterol(HDL-C)and SFRP5(r=0.20, 0.22,all P<0.01); SFRP5 was negatively correlated with BMI,WHR,the course of diabetes, TG, low density lipoprotein cholesterol(LDL-C), HbA1c, FINS, HOMA-IR(r=-0.38--0.13, all P<0.05),and positively correlated HDL-C and Irisin(r=0.17,0.22,all P<0.05).Multiple stepwise regression analysis showed that BMI, WHR and FINS were significantly negatively associated with serum Irisin(β=-0.04,-2.75,-2.27,all P<0.05), and BMI was significantly negatively associated with serum SFRP5(β=-1.14, P<0.05).Conclusion Serum Irisin and SFRP5 levels are decreased in diabetic patients with obesity,and may play important roles in the occurrence and development of diabetes accompanied with obesity.

参考文献/References:


[1] Al-Daghri NM,Mohammed AK,Al-Attas OS,et al. SNPs in FNDC5(irisin)are associated with obesity and modulation of glucose and lipid metabolism in Saudi subjects[J].Lipids Health Dis,2016,15:54. DOI:10.1186/s12944-016-0224-5.
[2] Carstensen-Kirberg M,Hatziagelaki E,Tsiavou A,et al.Sfrp5 associates with beta-cell function in humans[J].Eur J Clin Invest,2016,46(6):535-543.DOI:10.1111/eci.12629.
[3] 张云良,殷俏,郭淑芹,等.2型糖尿病患者视网膜病变与视黄醇结合蛋白4和胰岛素抵抗的相关性研究[J].微循环杂志,2016,26(2):56-59. DOI:10.3969/j.issn.1005-1740.2016.02.014.
[4] 中华医学会内分泌学分会.中国2型糖尿病合并肥胖综合管理专家共识[J].中华糖尿病杂志,2016,32(8):662-666.DOI:10.3760/cma.j.issn.1000-6699.2016.08.001.
[5] 田文葭,周华丽,李成江.2型糖尿病患者血清鸢尾素水平与胰岛素抵抗的相关性[J].中华糖尿病杂志,2014,6(9):655-659. DOI:10.3760/cma.j.issn.1674-5809.2014.09.007.
[6] Kristensen JM,Skov V,Petersson SJ,et al. A PGC-1α- and muscle fibre type-related decrease in markers of mitochondrial oxidative metabolism in skeletal muscle of humans with inherited insulin resistance[J].Diabetologia,2014,57(5):1006-1015. DOI:10.1007/s00125-014-3187-y.
[7] Jang HB,Kim HJ,Kang JH,et al.Association of circulating irisin levels with metabolic and metabolite profiles of Korean adolescents[J].Metabolism,2017,73:100-108.DOI:10.1016/j.metabol.2017.05.007.
[8] Leung PS. The potential of irisin as a therapeutic for diabetes[J]. Future Med Chem,2017,9(6):529-532.DOI:10.4155/fmc-2017-0035.
[9] Zhang C,Ding Z,Lv G,et al. Lower irisin level in patients with type 2 diabetes mellitus: a case-control study and meta-analysis[J].J Diabetes,2016,8(1):56-62.DOI:10.1111/1753-0407.12256.
[10] 陈恺情,卜瑞芳. Irisin--可否让代谢性疾病治疗进入新时代[J].国际内分泌代谢杂志,2016,36(1):38-41,51.DOI:10.3760/cma.j.issn.1673-4157.2016.01.009.
[11] Tan X,Wang X,Chu H,et al. SFRP5 correlates with obesity and metabolic syndrome and increases after weight loss in children[J].Clin Endocrinol(Oxf),2014,81(3):363-369. DOI:10.1111/cen.12361.
[12] Nakamura K,Fuster JJ,Walsh K. Adipokines: a link between obesity and cardiovascular disease[J].J Cardiol,2014,63(4):250-259.DOI:10.1016/j.jjcc.2013.11.006.
[13] 李宏刚,张美真,谭新睿,等. 血清分泌型卷曲相关蛋白5水平与儿童代谢综合征的关系[J].中国儿童保健杂志,2016,24(7):678-681.DOI:10.11852/zgetbjzz2016-24-07-03.
[14] 朱云霞,钟远. 分泌型卷曲相关蛋白5与肥胖及相关代谢性疾病的研究进展[J].中国糖尿病杂志,2016,24(4):371-373. DOI:10.3969/j.issn.1006-6187.2016.04.020.
[15] Guan B,Li W,Li F,et al.Sfrp5 mediates glucose-induced proliferation in rat pancreatic β-cells[J].J Endocrinol,2016,229(2):73-83. DOI:10.1530/JOE-15-0535.

相似文献/References:

[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍:2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.01.007]
 Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):31.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.01.008]
 Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):35.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
 Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(01):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
 Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
 Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(01):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
 Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
 Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(01):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
 Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(01):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81500644); 河北省医学科学研究重点课题计划(20160282); 保定市科学技术研究与发展指导计划(17ZF036)
通信作者:张云良,Email:nfmzyl@163.com
更新日期/Last Update: 2018-01-30